drugset / Trial / NCT06550830
Clinical Trial of PCV24 in Children Aged 2-17 Years
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, controlled combined with open-label phase Ia clinical trial.
Timeline
- Start
- 2024-09-07
- Primary completion
- 2025-06-25
- Completion
- 2025-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prevnar 13 | Vaccine | — | Intramuscular |
| Subject | Sinovac PCV24 formulation 1 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Sinovac PCV24 formulation 2 | Vaccine | 0.5 ml | Intramuscular |